Economics of individualization in comparative effectiveness research and a basis for a patient-centered health care

Journal of Health Economics

Volumn 30, Issue 3, 2011, Pages 549-559

  Basu, Anirban ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NATIONAL BUREAU OF ECONOMIC RESEARCH   (United States)

Author keywords

Comparative effectiveness research; Individualization; Latent factor models; Potential outcomes

Indexed keywords

COMPARATIVE STUDY; DATA SET; DEMAND ANALYSIS; ECONOMETRICS; ECONOMIC ACTIVITY; HEALTH CARE; WELFARE PROVISION;

ARTICLE; COMPARATIVE EFFECTIVENESS; CRIME; DRUG DEPENDENCE TREATMENT; HEALTH CARE NEED; HEALTH ECONOMICS; HUMAN; MEDICAL DECISION MAKING; PATIENT CARE;

ADULT; COMPARATIVE EFFECTIVENESS RESEARCH; DECISION MAKING; FEMALE; HUMANS; INSURANCE CARRIERS; MALE; MODELS, ECONOMETRIC; PATIENT PARTICIPATION; PATIENT-CENTERED CARE; PHYSICIAN-PATIENT RELATIONS; RESEARCH DESIGN; RISK ASSESSMENT; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

UNITED STATES;

EID: 79957880136     PISSN: 01676296     EISSN: 18791646     Source Type: Journal    
DOI: 10.1016/j.jhealeco.2011.03.004     Document Type: Article

References (63)

1. ACES Testimony, 2009. Testimony on comparative effectiveness research by the Alliance of Comparative Effectiveness Stakeholders (ACES) to the Dr. Carolyn M. Clancy, Director Agency for Healthcare Research and Quality (AHRQ). Available from: (accessed 31.01.11.). http://www.ahrq.gov/about/nac/aces.htm.
2. Basu A. Individualization at the heart of comparative effectiveness research: the time for i-CER has come. Medical Decision Making 2009, 29(6):N9-N11.
3. Basu A., Meltzer D. Value of information on preference heterogeneity and individualized care. Medical Decision Making 2007, 27(2):112-127.
4. Basu A., Paltiel D.A., Pollack H.A. Social costs of robbery and the cost-effectiveness of substance abuse treatment. Health Economics 2008, 17(8):926-948.
5. Basu A., Philipson T. Impact of comparative effectiveness research on health and healthcare spending. NBER Working Paper No. w15633 2010.
6. Bertrand M., Duflo E., Mullainathan S. How much should we trust differences-in-differences estimates?. The Quarterly Journal of Economics 2004, 119(1):249-275.
7. Chakley M., Khalil F. Third party purchasing of health services: patient choice and agency. Journal of Health Economics 2005, 24:1132-1153.
8. Cheng Y., Berry D.A. Optimal adaptive randomized designs for clinical trials. Biometrika 2007, 94(3):673-689.
9. Congressional Budget Office, January 2008. Technological change and the growth of health care spending. Available from: (accessed 30.06.09.). http://www.cbo.gov/ftpdocs/89xx/doc8947/01-31-TechHealth.pdf.
10. Dehejia R.H. Program evaluation as a decision problem. Journal of Econometrics 2005, 125:141-173.
11. Dismuke C., French M., et al. Out of touch or on the money: do the clinical objectives of addiction treatment coincide with economic evaluation results?. Journal of Substance Abuse Treatment 2004, 27:253-263.
12. Federal Coordinating Council for Comparative Effectiveness Research, 2009. Report to the President and the Congress. Available from: (accessed 30.06.09.). http://www.hhs.gov/recovery/programs/cer/cerannualrpt.pdf.
13. Fendrick A.M., Smith D.G., Chernew M.E., Shah S.N. A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost. American Journal of Managed Care 2001, 7:861-867.
14. French M., Salomé J., et al. Benefit-cost analysis of addiction treatment: methodological guidelines and empirical application using the DATCAP and ASI. Health Services Research 2002, 37(2):433-455.
15. Flynn P, Simpson D., Anglin M., et al. Comment on nonresponse and selection bias in treatment follow-up studies. Substance Use and Misuse 2001, 36(12):1753-1757.
16. Fisher R.A. The Design of Experiments 1935, Oliver and Boyd, Edinburgh.
17. Florens J.P., Heckman J.J., Meghir C., Vytlacil E. Identification of treatment effects using control functions in models with continuous, endogenous treatment and heterogeneous effects. Econometrica 2008, 76(5):1191-1206.
18. Garber A.M., Tunis S. Does comparative effectiveness research threaten personalized medicine. The New England Journal of Medicine 2009, 360(19):1925-1927.
19. Gelman A., Rubin D.B. Inference from iterative simulation using multiple sequences (with discussion). Statistical Sciences 1992, 7:457-511.
20. Gerstein D., Johnson R. Nonresponse and selection bias in treatment follow-up studies. Substance Use and Misuse 2000, 35(6-8):971-1014.
21. Gerstein D., Johnson R. In reply to Patrick M. Flynn and colleagues. Substance Use and Misuse 2001, 36(12):1753-1757.
22. Heckman J.J. Dummy endogenous variables in a simultaneous equations system. Econometrica 1978, 46(4):931-959.
23. Heckman J.J. Varieties of selection bias. American Economic Review 1990, 80:313-318.
24. Heckman J.J. Evaluating Welfare and Training Programs 1992, Manski and Garfinkel.
25. Heckman J.J., Robb R. Alternative methods for evaluating the impact of interventions. Longitudinal Analysis of Labor Market Data. Econometric Society Monograph No. 10 1985, Cambridge University Press, Cambridge. J. Heckman, B. Singer (Eds.).
26. Heckman J.J., Smith J. Evaluating the welfare state. Econometrics in the 20th Century: The Ragnar Frisch Centenary. Econometric Society Monograph Series 1998, Cambridge University Press, Cambridge. S. storm (Ed.).
27. Heckman J.J., Navarro S. Dynamic discrete choice and dynamic treatment effects. Journal of Econometrics 2007, 136(2):341-396.
28. Heckman J.J., Vytlacil E.J. Local instrumental variables and latent variable models for identifying and bounding treatment effects. Proceedings of the National Academy of Sciences of the United States of America 1999, 96(8):4730-4734.
29. Holland P. Statistics and causal inference. Journal of the American Statistical Association 1986, 81:945-970.
30. Jena A., Philipson T.J. Endogenous Cost-effectiveness Analysis in Health Care Technology Adoption. NBER Working Papers 15032 2009.
31. LaLonde R. Evaluating the econometric evaluations of training programs with experimental data. American Economic Review 1986, 76(4):604-620.
32. Manning W.G., Marquis M.S. Health insurance: the trade-off between risk pooling and moral hazard. Journal of Health Economics 1996, 15(5):609-639.
33. Manski C. Maximum score estimation of the stochastic utility model of choice. Journal of Econometrics 1975, 3:205-228.
34. Manski C., Garfinkel I. Evaluating Welfare and Training Programs 1992, Harvard University Press, Cambridge.
35. McLellan A.T., Woody G.E., Metzger D., et al. Evaluating the effectiveness of addiction treatments: reasonable expectations, appropriate comparisons. Milbank Quarterly 1996, 74(1):51-85.
36. McCollister K., French M. The relative contribution of outcome domains in the total economic benefit of addiction interventions: a review of first findings. Addiction 2003, 98:1647-1659.
37. McFadden D. Conditional logit analysis of qualitative choice behavior. Frontiers of Econometrics 1974, Academic Press, New York. P. Zarembka (Ed.).
38. Report to Congress: Reforming the Delivery System MedPAC. Chapter 5: Barack Obama and Joe Biden's Plan to Lower Health Care Costs and Ensure Affordable, Accessible Health Coverage For All 2008, (accessed 05.12.08).
39. Meltzer D., Huang E., Jin L., Shook M., Chin M. Major bias in cost-effectiveness analysis due to failure to account for self-selection: impact in intensive therapy for type 2 diabetes among the elderly. Medical Decision Making (abstract) 2003, 23(6):576.
40. Meltzer D., Basu A., Conti R. The Economics of comparative effectiveness studies: societal and private perspectives and their implications for prioritizing public investments in comparative effectiveness research. PharmacoEconomics 2010, 28(10):843-853.
41. Munkin M.K., Trivedi P.K. Bayesian analysis of self-selection model with multiple outcomes using simulation-based estimation: an application to the demand for healthcare. Journal of Econometrics 2003, 114:197-220.
42. Murphy S.A. An experimental design for the development of adaptive treatment strategies. Statistics in Medicine 2005, 24:1455-1481.
43. Neyman J. Sur les applications de la thar des probabilities aux experiences Agaricales: Essay des principle 1923, French (English translation of excerpts by Dabrowska, D., Speed, T., 1990. Statistical Sciences 5, 463-472).
44. Pauly M.V. The economics of moral hazard: comment. The American Economic Review 1968, 58(3):531-537.
45. Pauly M.V. Adverse selection and moral hazard: Implications for health insurance markets. Incentives and Choice in Health and Health Care 2008, MIT Press, Cambridge, MA. F. Sloan, H. Kasper (Eds.).
46. Pauly M.V., Blavin F.E. Moral hazard in insurance, value-based cost sharing, and the benefits of blissful ignoring. Journal of Health Economics 2008, 27(6):1407-1417.
47. Pauly M.V., Held P.J. Benign moral hazard and cost-effectiveness analysis of insurance coverage. Journal of Health Economics 1990, 9(4):447-461.
48. Quandt R.E. The estimation of parameters of a linear regression system obeying two separate regimes. Journal of the American Statistical Association 1958, 53(284):873-880.
49. Quandt R.E. A new approach to estimating switching regression. Journal of the American Statistical Association 1972, 67(338):306-310.
50. Roy A.D. Some thoughts on the distribution of earnings. Oxford Economic Papers 1951, 3:135-146.
51. Rubin D. Estimating causal effects of treatment in randomized and non-randomized studies. Journal of Educational Psychology 1974, 66:688-701.
52. Rubin D. Bayesian inference for causal effects: the role of randomization. Annals of Statistics 1978, 6:34-58.
53. Sculpher M.J. Subgroups and heterogeneity in cost-effectiveness analysis. PharmacoEconomics 2008, 26:799-806.
54. Senn S., Hoboken N.J. Cross-over Trials in Clinical Research 2002, Wiley. 2nd ed.
55. Simpson D.D., Joe G.W., Broome K.M. A national 5-year follow-up of treatment outcomes for cocaine dependence. Archives of General Psychiatry 2002, 59:538-544.
56. Sindelar J., Jofre-Bonet M., et al. Cost-effectiveness analysis of addiction treatment: paradoxes of multiple outcomes. Drug and Alcohol Dependence 2004, 73:41-50.
57. Sisko A., Truffer C., Smith S., Keehan S., Cylus J., Poisal J.A., Clemens M.K., Lizonitz J. Health spending projections through 2018: recession effects add uncertainty to the outlook. Health Affairs 2009, w346-w357. (web exclusive).
58. Stinnett A.A., Mullahy J. Net Health benefits: a framework for the analysis of uncertainty in cost-effectiveness analysis. Medical Decision Making 1998, 18(2 Suppl):S68-S80.
59. Stroup T.S., McEvoy J.P., Swartz M.S., Byerly M.J., Glick I.D., Canive J.M., McGee M.F., Simpson G.M., Stevens M.C., Lieberman J.A. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophrenia Bulletin 2003, 29(1):15-31.
60. Thaler R., Rosen S. The value of saving a life: evidence from the labor market. Household Production and Consumption 1975, National Bureau of Economic Research, New York. E. Nestor, Terleckyj (Eds.).
61. Tunis S.R., Stryer D.B., Clancy C.M. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. Journal of the American Medical Association 2003, 290:1624-1632.
62. Vanness D.J., Mullahy J. Perspectives on mean-based evaluation of health care. The Elgar Companion to Health Economics 2006, Edward Elgar Publishing, Cheltenham. A. Jones (Ed.).
63. Zarkin G., Dunlap L., Bray J., et al. The effect of treatment completion and length of stay on employment and crime in outpatient drug-free treatment. Journal of Substance Abuse Treatment 2002, 23(4):261-267.